NEW YORK – Novigenix said today that it has tapped Belgium-based startup bioinformatics firm BioLizard to develop an artificial intelligence-based algorithm to support the transition of its Colox immuno-transcriptomic RT-PCR product onto a new platform. The algorithm will also underlie new Novigenix products under development.
Switzerland-based Novigenix is in the process of migrating Colox, an mRNA-based assay for early detection of colorectal cancer development, to the new LITOseek system, which relies on next-generation sequencing rather than RT-PCR. LITOseek previously had been dubbed Colox+.
"Partnering with BioLizard helps us to fast-track the development of our LITOseek platform," Novigenix CEO Jan Groen said in a statement. "Our current Colox customers will strongly benefit from this new development once we launch our new colon cancer test on the LITOseek platform, but it will also fast-track the progress of new products that are currently in the pipeline."
Financial and other terms of the deal were not disclosed.